Figure 6
p66Shc levels and clinical behavior of U-CLL and M-CLL. (A) Ratios of the relative levels of Bcl-2/p66Shc and Bcl-xL/p66Shc transcripts (top) and products of the relative levels of Bax*p66Shc and Bak*p66Shc transcripts (bottom) measured by qRT-PCR in B cells from the 64 patients with CLL. Each value is shown as a dot. Gray dots correspond to the patients with M-CLL, black dots to the patients with U-CLL. The line shows the median value of the ratios (top) or products (bottom). The differences between the M-CLL and U-CLL subsets (calculated on the mean values) were statistically significant, as shown in each panel. (B) TFI (left) and OS (right) in patients with CLL with Bcl-2/p66Shc transcript ratios above and below median value.

p66Shc levels and clinical behavior of U-CLL and M-CLL. (A) Ratios of the relative levels of Bcl-2/p66Shc and Bcl-xL/p66Shc transcripts (top) and products of the relative levels of Bax*p66Shc and Bak*p66Shc transcripts (bottom) measured by qRT-PCR in B cells from the 64 patients with CLL. Each value is shown as a dot. Gray dots correspond to the patients with M-CLL, black dots to the patients with U-CLL. The line shows the median value of the ratios (top) or products (bottom). The differences between the M-CLL and U-CLL subsets (calculated on the mean values) were statistically significant, as shown in each panel. (B) TFI (left) and OS (right) in patients with CLL with Bcl-2/p66Shc transcript ratios above and below median value.

Close Modal

or Create an Account

Close Modal
Close Modal